Search results
12 sie 2024 · At Syndax, we are advancing the next generation of targeted treatments to realize a future in which people with cancer live longer and better than ever before. We are a commercial stage oncology innovator seeking to develop first-in-class therapies in areas of significant unmet need such as acute leukemia and chronic graft-versus-host disease.
- Investors
Syndax Pharmaceuticals is a commercial stage...
- Join Us
At Syndax, we are reimagining how cancer is treated with a...
- Press Releases
Syndax Pharmaceuticals Reports First Quarter 2024 Financial...
- Events & Presentations
Syndax ASH Annual Meeting Data Update Call. 12.11.22 / 9:00...
- Investors
Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of first-in-class therapies in areas of high unmet need. Highlights of the Company’s pipeline include a highly selective menin inhibitor for acute leukemia and a monoclonal antibody that blocks the CSF-1 receptor for chronic graft-versus ...
5 gru 2022 · Revumenib is a menin inhibitor that received Breakthrough Therapy Designation from the FDA for the treatment of R/R KMT2A-rearranged acute leukemia. The company presented Phase 1 data at ASH Annual Meeting showing a 27% CR/CRh rate in KMT2A patients treated at RP2D.
We have a proven ability to advance innovative and differentiated cancer programs and a strong record of adhering to scientific excellence, following promising clinical data and real-world utilization.
Find the latest Syndax Pharmaceuticals, Inc. (SNDX) stock quote, history, news and other vital information to help you with your stock trading and investing.
29 lip 2024 · Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
2 lis 2023 · Revumenib is a menin inhibitor for acute leukemias with genomic alterations. See updated data from pivotal and Phase 1/2 trials, including ORR, MRD, and safety results.
